
Joshua LaBaer, PhD, reviews a national study he led that linked pre-existing antimicrobial antibodies with subsequent COVID-19 vaccine response.

Joshua LaBaer, MD, PhD, is the executive director of the Biodesign Institute at Arizona State University.